Eledon Pharmaceuticals Inc logo

Eledon Pharmaceuticals Inc(ELDN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.78
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ELDN

11/20/2026: ELDN (1-star) is currently NOT-A-BUY. Pass it for now.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ transplantation and autoimmune conditions. Its primary strength lies in its lead candidate, tegoprubart, an anti-CD40L antibody demonstrating promising Phase 2 results that suggest a safer alternative to toxic legacy immunosuppressants. The core investment opportunity rests on this 'pipeline-in-a-product' asset expanding across kidney, liver, and cell transplantation markets. However, the company faces substantial execution risks, a pre-revenue financial profile, and heavy reliance on clinical trial outcomes and capital markets. It represents a speculative fit for growth-oriented investors willing to monitor upcoming late-stage clinical readouts and regulatory updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveOffers high-risk, high-reward exposure to a novel clinical-stage immunology pipeline with multi-indication market potential.
Momentum investorStrong fit while signal remains positiveStock price frequently reacts sharply to clinical trial readouts, regulatory updates, and biotech sector sentiment swings.
Value investorWeak fitLacks current commercial revenues, positive earnings, or traditional valuation support metrics.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitExhibits high clinical binary risk, equity volatility, and regular cash-burn exposure typical of developmental biotech.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience severe price fluctuations based on trial data announcements and regulatory news.
Valuation riskHighValuations are driven by speculative future success probabilities rather than current operating profits or cash flows.
Competition risk (large pharmaceutical immunotherapy rivals)HighWell-capitalized competitors can advance alternative immunology pipelines faster or with broader resources.
Business qualityMediumThe company centers on a scientifically validated target, but lacks commercial commercialization history.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies heavily on executing complex, expensive late-stage clinical trials without safety setbacks.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 160.47M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 944.3K shares
Beta 0.96
52 Weeks Range 1.39 - 4.49
Updated Date 11/20/2026
52 Weeks Range 1.39 - 4.49
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.73

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -51.98%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ELDN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ELDN has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-26.1%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ELDN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ELDN's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-26.1%, negative) and free-cash-flow growth (-31.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 54.5% and approximately 92.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.32%, which materially reduces the ownership score.

Top 5 Institutional Investors

Bvf Inc 7.73%
BlackRock Inc 6.29%
Defilade Capital Management, L.P. 4.33%
Vanguard Capital Management, LLC 4.20%
The Goldman Sachs Group Inc 3.08%

Unit Economics (Per $1K Revenue)

★★★★★
ELDN generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.08% (Tax Credit)

Quantitative Style Profile

★★★★★
ELDN has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Therapeutics DevelopmentFuture potential commercial sales or licensing milestones of tegoprubart for organ and cell transplantation and autoimmune conditions.The company currently makes zero commercial revenue and operates entirely as a pre-commercial clinical-stage research enterprise.

Valuation

Trailing PE -
Forward PE 5.39
Enterprise Value 101.31M
Price to Sales(TTM) -
Enterprise Value 101.31M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.84
Shares Outstanding 84.46M
Shares Floating 77.79M
Shares Outstanding 84.46M
Shares Floating 77.79M
Percent Insiders 0.32
Percent Institutions 54.5

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.